Related Experiment Video
Updated: Jul 12, 2026

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
Published on: February 8, 2022
Hypoattenuated Leaflet Thickening: A Comprehensive Review of Contemporary Data
Nika Samadzadeh Tabrizi1, Gregory Fishberger2, Sridhar R Musuku1
1Department of Anesthesiology, Albany Medical Center, Albany, NY.
Insights
Hypoattenuated leaflet thickening (HALT) affects nearly one-third of patients after aortic valve replacement. This review examines HALT risk factors, prevention, and treatment for better patient outcomes.
Area of Science:
- Cardiology
- Cardiac Surgery
- Radiology
Background:
- Hypoattenuated leaflet thickening (HALT) is common after surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR).
- HALT often indicates subclinical leaflet thrombosis but can progress to valve dysfunction.
- There is no current consensus on HALT screening or management.
Purpose of the Study:
- To comprehensively review the evidence on risk factors, prevention, treatment, and prognosis of HALT.
- To address the clinical significance and management of HALT in patients post-SAVR and TAVR.
Main Methods:
- Systematic review of existing literature on HALT.
- Evaluation of studies reporting on risk factors, clinical presentation, and outcomes of HALT.
- Analysis of current screening and management strategies.
Main Results:
- HALT affects approximately one-third of patients within one year of SAVR or TAVR.
- HALT is often incidentally detected in asymptomatic patients.
- Progression of HALT can lead to leaflet immobility and valve deterioration.
Conclusions:
- Further research is needed to clarify the clinical significance of HALT.
- Establishing standardized screening and management protocols for HALT is crucial.
- Understanding HALT is essential for optimizing long-term outcomes after aortic valve replacement.
Abstract:
Nearly one-third of patients who undergo surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) develop hypoattenuated leaflet thickening (HALT) within a year. HALT typically represents subclinical leaflet thrombosis in asymptomatic patients, and as a result it often is detected incidentally. However, HALT also may worsen in severity, resulting in leaflet immobility and/or valve deterioration. The clinical significance of HALT is a topic of ongoing debate, and currently there is no consensus on the screening and management of HALT in patients following TAVR or SAVR. This review provides a comprehensive evaluation of the available evidence on risk factors, preventative measures, treatment, and prognosis for this growing patient cohort.
More Related Videos
12:15Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease
Published on: February 8, 2022
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
Related Concept Videos
Mitral Valve Prolapse I: Introduction
Mitral Valve Prolapse II: Assessment and Management
Mitral Regurgitation I: Introduction
Mitral Regurgitation III: Medical Management
Aortic Regurgitation I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies